3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
Pemetrexed
13
Cisplatin
12
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cyclophosphamide
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
fludarabine
3
defactinib
3
amatuximab
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
tremelimumab
1
tazemetostat
1
osimertinib
1
napabucasin
1
enzalutamide
1
bemcentinib
1
abemaciclib
1
VS-5584
1
Trabectedin
1
Thiostrepton
1
Safety
1
Panobinostat
1
Monatide (IMS 3015)
1
Midazolam
1
Letrozole
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma, Malignant
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled